To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Beactica Extends Fragment-Based Discovery Research Services Agreement
Beactica has announced that it has added a project under its ongoing research services agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV.
Under the research services agreement, Beactica will use its proprietary drug discovery platform Sprint™ to identify novel allosteric modulators targeting undisclosed central nervous system (CNS) proteins of therapeutic interest to Janssen. Financial terms of the agreement were not disclosed.
“We are pleased to extend our collaboration with Janssen and look forward to further supporting their efforts to discover innovative medicines” said Beactica CEO, Dr Per Källblad.
Dr Källblad continued, “The extension of our relationship testifies to the ability of our Sprint™ platform to generate novel, high-quality medicinal chemistry starting points against challenging drug targets”.
Beactica initiated their first research services project with Janssen in early 2011.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
